2006
Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox
Chin KM, Foss FM. Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox. Clinical Lymphoma Myeloma & Leukemia 2006, 7: 199-204. PMID: 17229335, DOI: 10.3816/clm.2006.n.059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCD4-Positive T-LymphocytesClinical Trials as TopicDiphtheria ToxinFemaleHumansInterleukin-2Interleukin-2 Receptor alpha SubunitLymphoma, T-Cell, CutaneousMaleMiddle AgedMycosis FungoidesReceptors, Interleukin-2Recombinant Fusion ProteinsSkin NeoplasmsTreatment OutcomeConceptsCutaneous T-cell lymphomaAdvanced stage diseaseT-cell lymphomaDenileukin diftitoxMedian survivalBiologic correlatesAdvanced-stage cutaneous T-cell lymphomaResponse ratePhase III registration trialNumber of CD4Single-center seriesAbsolute lymphocyte countOverall response rateT cell populationsCourse of therapyLymphocyte countClinical responseLymphocyte populationsDisease progressionDiftitoxPatientsRegistration trialsHuman interleukinLactate dehydrogenaseSurvivalImmunomodulatory Effects of Rexinoids
Foss F. Immunomodulatory Effects of Rexinoids. Seminars In Oncology 2006, 33: 21-25. PMID: 16516672, DOI: 10.1053/j.seminoncol.2005.12.019.Peer-Reviewed Original ResearchConceptsImmunomodulatory effectsCutaneous T-cell lymphomaReceptor-targeted therapyImproved clinical outcomesT-cell lymphomaPractical clinical approachExtracorporeal photophoresisClinical outcomesDenileukin diftitoxTherapy optionsHematologic malignanciesClinical activityPharmacotherapeutic agentsLymphoid malignanciesClinical approachTumor cellsRexinoidsMalignancyTreatmentDiftitoxLymphomaTherapyClinical Experience With Denileukin Diftitox (ONTAK)
Foss F. Clinical Experience With Denileukin Diftitox (ONTAK). Seminars In Oncology 2006, 33: 11-16. PMID: 16516670, DOI: 10.1053/j.seminoncol.2005.12.017.Peer-Reviewed Original ResearchConceptsIL-2 receptorCutaneous T-cell lymphomaT-cell lymphomaDenileukin diftitoxIntermediate affinity IL-2 receptorsHuman IL-2 receptorChronic lymphocytic leukemiaActivated T lymphocytesDiphtheria toxinClinical profileHodgkin's lymphomaHematologic disordersT lymphocytesLymphocytic leukemiaB cellsClinical experienceB lymphocytesLymphomaCytocidal actionNumber of leukemiasDiftitoxHigh affinity formCellular protein synthesisReceptorsLymphocytes
2005
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma
Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005, 106: 454-457. PMID: 15811959, DOI: 10.1182/blood-2004-11-4570.Peer-Reviewed Original ResearchConceptsRefractory cutaneous T-cell lymphomaCutaneous T-cell lymphomaPhase 1 trialT-cell lymphomaDenileukin diftitoxInterleukin-2High-affinity IL-2 receptorGrade 4 lymphopeniaLeukemia cellsIL-2R expressionIL-2 receptorT-cell leukemia cellsCD25 expressionIL-2RVivo upregulationP75 subunitDiftitoxGrade 2BexaroteneLow dosesPatientsLymphoma cellsBiomodulatory effectDiphtheria toxinLymphoma
2003
Interleukin-2 receptor–directed therapies for cutaneous lymphomas
Foss FM, Waldmann TA. Interleukin-2 receptor–directed therapies for cutaneous lymphomas. Hematology/Oncology Clinics Of North America 2003, 17: 1449-1458. PMID: 14710895, DOI: 10.1016/s0889-8588(03)00110-2.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsGene Expression Regulation, NeoplasticHumansImmunoconjugatesImmunotherapyImmunotoxinsInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsProtein IsoformsProtein SubunitsReceptors, Interleukin-2Recombinant Fusion ProteinsRetinoidsSkin NeoplasmsConceptsT-cell lymphomaIL-2RIL-2/IL-2R systemPeripheral T-cell lymphomaAnaplastic large cell lymphomaNatural killer lymphomaReceptor-directed therapyIL-2R systemIL-2 receptorLarge cell lymphomaRational therapeutic strategiesIL-2R subunitsCutaneous lymphomasSpecific immunotherapyIL-2Cell lymphomaTherapeutic strategiesLymphomaHumanized antibodyCTCLBeta-emitting radionuclidesAntibodiesImmunotherapyTherapyAgents
2002
Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene
Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leukemia Research 2002, 26: 1077-1083. PMID: 12443879, DOI: 10.1016/s0145-2126(02)00059-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArginineButyratesCell SurvivalCyclic AMPDiphtheria ToxinDose-Response Relationship, DrugDrug SynergismHumansInterleukin-2Interleukin-2 Receptor beta SubunitLeukemiaLymphomaReceptors, InterleukinReceptors, Interleukin-2Recombinant Fusion ProteinsResponse ElementsSecond Messenger SystemsUp-RegulationConceptsCutaneous T-cell lymphomaIL-2R expressionNon-Hodgkin lymphomaArginine butyrateIL-2RLow affinity IL-2RHistone deacetylaseDirect growth-inhibitory effectB-cell non-Hodgkin lymphomaHigh-affinity IL-2 receptorLeukemia cellsCAMP response elementT-cell lymphomaIL-2 receptorNative diphtheria toxinGrowth inhibitory effectsClinical trialsP75 subunitAchievable concentrationsResponse rateVitro dataDAB389IL-2Interleukin-2 geneTumor cellsLymphoma cellsImmunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox
Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002, 100: 1399-1403. PMID: 12149223, DOI: 10.1182/blood-2002-01-0300.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAlitretinoinAntineoplastic AgentsBexaroteneB-LymphocytesDiphtheria ToxinGene Expression RegulationHumansInterleukin-2Leukemia, Lymphocytic, Chronic, B-CellLeukemia-Lymphoma, Adult T-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Interleukin-2Receptors, Retinoic AcidRecombinant Fusion ProteinsRetinoid X ReceptorsRetinoidsTetrahydronaphthalenesT-LymphocytesTranscription FactorsTretinoinTumor Cells, CulturedConceptsRetinoic acid receptorsImmunomodulatory effectsIL-2RHigh affinity IL-2R expressionCutaneous T-cell lymphomaHigh affinity IL-2R.Interleukin-2 receptor expressionIL-2R expressionT-cell lymphomaB cell leukemia cellsB-cell leukemiaT-cell leukemiaMechanism of actionAutoimmune diseasesHematologic malignanciesClinical activityReceptor expressionLymphoid malignanciesIL-2R.Retinoid X receptor (RXR) familyP75 subunitAcid receptorsRexinoid receptorsLeukemia cellsRexinoids